864 related articles for article (PubMed ID: 25902198)
21. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
Kim SJ; Koo PJ; Chang S
Cancer Chemother Pharmacol; 2016 Apr; 77(4):723-31. PubMed ID: 26891957
[TBL] [Abstract][Full Text] [Related]
22.
Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
[TBL] [Abstract][Full Text] [Related]
23. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.
Gabriel E; Alnaji R; Du W; Attwood K; Kukar M; Hochwald S
Ann Surg Oncol; 2017 Jun; 24(6):1739-1746. PubMed ID: 28058562
[TBL] [Abstract][Full Text] [Related]
27. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
28. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA
Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of PET-CT in predicting survival in patients with esophageal cancer.
Brown C; Howes B; Jamieson GG; Bartholomeusz D; Zingg U; Sullivan TR; Thompson SK
World J Surg; 2012 May; 36(5):1089-1095. PubMed ID: 22374537
[TBL] [Abstract][Full Text] [Related]
30. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.
Giorgetti A; Pallabazzer G; Ripoli A; Solito B; Genovesi D; Lencioni M; Fabrini MG; D'Imporzano S; Pieraccini L; Marzullo P; Santi S
Medicine (Baltimore); 2016 Mar; 95(13):e3151. PubMed ID: 27043676
[TBL] [Abstract][Full Text] [Related]
32. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.
Zhang H; Tan S; Chen W; Kligerman S; Kim G; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):195-203. PubMed ID: 24189128
[TBL] [Abstract][Full Text] [Related]
33. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
35. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
Tandberg DJ; Cui Y; Rushing CN; Hong JC; Ackerson BG; Marin D; Zhang X; Czito BG; Willett CW; Palta M
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1002-1007. PubMed ID: 30055238
[TBL] [Abstract][Full Text] [Related]
36. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
37. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Rizk NP; Tang L; Adusumilli PS; Bains MS; Akhurst TJ; Ilson D; Goodman K; Rusch VW
J Thorac Oncol; 2009 Jul; 4(7):875-9. PubMed ID: 19487968
[TBL] [Abstract][Full Text] [Related]
39. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
40. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
